← 홈

ADC

1,032개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,032개
ADCBiologicstaleSpectrum Pharmaceuticals, IncPhase 1

Poziotinib (Poziotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 30%임상시험 24상태 DISCONTINUED
ADCBiologicstaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 44%임상시험 24상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

U3-1402 (U3-1402)

Metastatic Breast Cancer; Advanced Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 ACTIVE
ADCBiologicstaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 27.8%임상시험 23상태 ACTIVE
ADCBiologicstaleTaiho Oncology, Inc.Phase 2

Futibatinib (Futibatinib)

Advanced Solid Tumor · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 47.1%임상시험 23상태 RECRUITING
ADCBiologicstaleAlliance Foundation Trials, LLC.Phase 2

Giredestrant (Giredestrant)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 50%임상시험 23상태 RECRUITING
ADCBiologicstaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 1%임상시험 23상태 RECRUITING
ADCBiologicstaleYOUNGIL KOHPhase 2

Mezigdomide (Mezigdomide)

Relapsed Refractory Multiple Myeloma (RRMM) · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 23상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Nemtabrutinib (Nemtabrutinib)

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma; Gastric Mucosa-Associated Lymphoid Tissue Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0.0%임상시험 23상태 RECRUITING
ADCBiologicstaleShanghai Henlius BiotechPhase 3

TCbHP (TCbHP)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 23상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

HER3-DXd (HER3-DXd)

Carcinoma, Non-Small-Cell Lung · HER3

#HER3#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 56%임상시험 22상태 RECRUITING
ADCBiologicstaleHansoh BioMedical R&D CompanyPhase 2

HS-20093 (HS-20093)

Advanced Solid Tumor · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 22상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 1

MEDI5752 (MEDI5752)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 22상태 RECRUITING
ADCBiologicstaleInstitut du Cancer de Montpelli…Phase 1

TDM1 (TDM1)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 9.3%임상시험 22상태 ACTIVE
ADCBiologicstaleDualityBio Inc.Phase 2

BNT327 (BNT327)

Solid Tumors · Solid Tumors

#SolidTumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 21상태 RECRUITING
ADCBiologicstaleCelgenePhase 2

CC-99282 (CC-99282)

Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 21상태 RECRUITING
ADCBiologicstaleInnovent Biologics (Suzhou) Co.…Phase 2

IBI363 (IBI363)

Rare Malignant Neoplasm; Advanced Solid Tumors · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 21상태 RECRUITING
ADCBiologicstaleRisen (Suzhou) Pharma Tech Co.,…Preclinical

Pyrotinib Maleate Tablets (Pyrotinib Maleate Tablets)

HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 20상태 ACTIVE
ADCBiologicstaleDanish Breast Cancer Cooperativ…Phase 3

Ribociclib with ET (Ribociclib with ET)

Metastatic Breast Cancer; ER-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 20상태 DISCONTINUED
ADCBiologicstaleEli Lilly and CompanyPhase 2

Olutasidenib (Olutasidenib)

Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 2%임상시험 19상태 RECRUITING

19 / 52 페이지

← 이전다음 →